Cargando…

Type 1 diabetes mellitus induced by PD-1 inhibitors in China: a report of two cases

The immune-related adverse events associated with immunotherapy may affect endocrine glands and other tissues. Two Chinese patients with malignancies were treated with programmed cell death-1 (PD-1) inhibitors (nivolumab and pembrolizumab) and followed up with biochemical tests over 1 year. After PD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luo, Jingmei, Feng, Jiagang, Liu, Chunyan, Yang, Zhongce, Zhan, Dong, Wu, Yanan, Pan, Li, Zhang, Lihua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9523865/ https://www.ncbi.nlm.nih.gov/pubmed/36171723 http://dx.doi.org/10.1177/03000605221121940

Ejemplares similares

Two types of fulminant type 1 diabetes mellitus: Immune checkpoint inhibitor‐related and conventional
por: Imagawa, Akihisa
Publicado: (2020)

SAT-680 Diabetes Mellitus Induced by Programmed Cell Death-1 (PD-1) Inhibitors: A Case Report
por: Abuaisha, Munder, et al.
Publicado: (2020)

Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China
por: Liu, Si-Yang, et al.
Publicado: (2017)

Identification of CBPA as a New Inhibitor of PD-1/PD-L1 Interaction
por: Wang, Fengling, et al.
Publicado: (2023)

Association of PD-1 and PD-L1 Genetic Polymorphyisms with Type 1 Diabetes Susceptibility
por: Qian, Chenyue, et al.
Publicado: (2018)

A real-world retrospective study of incidence and associated factors of endocrine adverse events related to PD-1/PD-L1 inhibitors
por: Wang, Zhiyi, et al.
Publicado: (2023)

Chemokines in Type 1 Diabetes Mellitus
por: Pan, Xiongfeng, et al.
Publicado: (2022)

Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy
por: Ai, Leilei, et al.
Publicado: (2020)

PD-1 inhibitor-associated type 1 diabetes: A case report and systematic review
por: Lin, Cuiping, et al.
Publicado: (2022)

Efficacy and Safety of PD-1/PD-L1 Inhibitor Chemotherapy Combined with Lung Cancer Fang No. 1 in Relapsed and Refractory SCLC: A Retrospective Observational Study
por: Wang, Lihua, et al.
Publicado: (2022)

Determining the optimal PD‐1/PD‐L1 inhibitors for the first‐line treatment of non‐small‐cell lung cancer with high‐level PD‐L1 expression in China
por: Teng, Meng‐Meng, et al.
Publicado: (2021)

Current status of the clinical use of PD-1/PD-L1 inhibitors: a questionnaire survey of oncologists in China
por: Zhang, Bicheng, et al.
Publicado: (2020)

Fulminant type 1 diabetes mellitus: Two case reports
por: You, Wei, et al.
Publicado: (2019)

Efficacy and safety of adjuvant therapy with PD‑1/PD‑L1 inhibitors in cancer
por: Mo, Dun-Chang, et al.
Publicado: (2022)

PD-1/PD-L1 Inhibitors in Cervical Cancer
por: Liu, Yuncong, et al.
Publicado: (2019)

Use of SGLT-2 Inhibitors in Patients With Type 1 Diabetes Mellitus
por: El Hage, Lea, et al.
Publicado: (2020)

High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma
por: Chen, Xi, et al.
Publicado: (2022)

The Research Progress of PD-1/PD-L1 Inhibitors Enhancing Radiotherapy Efficacy
por: Wen, Lu, et al.
Publicado: (2021)

Value assessment of PD-1/PD-L1 inhibitors in the treatment of oesophageal and gastrointestinal cancers
por: Ou, Shun-Long, et al.
Publicado: (2023)

PD-1/PD-L1 Inhibitor Plus Chemotherapy Versus PD-1/PD-L1 Inhibitor in Microsatellite Instability Gastrointestinal Cancers: A Multicenter Retrospective Study
por: Chen, Mifen, et al.
Publicado: (2023)

Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
por: Yi, Ming, et al.
Publicado: (2018)

Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma
por: Jelinek, Tomas, et al.
Publicado: (2018)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
por: Liu, Jinhua, et al.
Publicado: (2021)

Ocular adverse events in PD-1 and PD-L1 inhibitors
por: Young, LeAnne, et al.
Publicado: (2021)

A d-peptide-based oral nanotherapeutic modulates the PD-1/PD-L1 interaction for tumor immunotherapy
por: Liu, Dan, et al.
Publicado: (2023)

Expression of PD-1 Molecule on Regulatory T Lymphocytes in Patients with Insulin-Dependent Diabetes Mellitus
por: Perri, Valentina, et al.
Publicado: (2015)

Efficacy and Safety of PD-1/PD-L1 Checkpoint Inhibitors versus Anti-PD-1/PD-L1 Combined with Other Therapies for Tumors: A Systematic Review
por: Zhang, Yiru, et al.
Publicado: (2023)

Efficacy of PD-1/PD-L1 inhibitors against pretreated advanced cancer: a systematic review and meta-analysis
por: Hu, Hao, et al.
Publicado: (2018)

SUN-170 Development of Type 1 Diabetes Mellitus on Immune Checkpoint Inhibitor
por: Tsuei, Jessica, et al.
Publicado: (2019)

Combined Hypophysitis and Type 1 Diabetes Mellitus Related to Immune Checkpoint Inhibitors
por: Fujita, Yasunori, et al.
Publicado: (2023)

Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series
por: Martini, Dylan J., et al.
Publicado: (2017)

Efficacy of PD‐1/PD‐L1 inhibitors in patients with non‐small cell lung cancer and brain metastases: A real‐world retrospective study in China
por: Sheng, Jiamin, et al.
Publicado: (2021)

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
por: Diggs, Laurence P., et al.
Publicado: (2017)

Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors
por: Anand, Kartik, et al.
Publicado: (2020)

PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases
por: Zhang, Ke, et al.
Publicado: (2022)

Overcoming resistance to PD-1/PD-L1 inhibitors in esophageal cancer
por: Cheng, Chao, et al.
Publicado: (2022)

Pulmonary pleomorphic carcinoma treated with PD‐1 inhibitor: Two case reports
por: Jiang, Tao, et al.
Publicado: (2023)

The efficacy of sodium glucose co-transport-2 inhibitors on glycemic control for patients with type 1 diabetes mellitus: A protocol for systematic review and meta-analysis
por: Zhang, Yajie, et al.
Publicado: (2021)

Total neoadjuvant treatment and PD-1/PD-L1 checkpoint inhibitor in locally advanced rectal cancer
por: Xiao, Weiwei, et al.
Publicado: (2023)

PD0325901, an ERK inhibitor, enhances the efficacy of PD-1 inhibitor in non-small cell lung carcinoma
por: Luo, Min, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ofd8af6c57bkub3hn82ib40puu